Immunotherapy

30 March -1 April 2020 | Business Design Centre London

 

 

2000+
Attendees
700+
1-2-1 Meetings
300+
Speakers
100+
Exhibitors
12
Streams

 

 

Immunotherapy

IMMUNOTHERAPY, Tuesday 31 March 2020

CONFERENCE DAY 1 - TUESDAY 31st March 2020

Opening Keynotes Day 1 – CAR-T & Immunotherapy focus

Prasad Adusumilli
09:00

Keynote presentaton: Autologous Mesothelin-targeting CAR-T to tackle solid tumours in the clinic

  • The presentation will highlight results to date of mesothelin-targeted CAR T-cell clinical trial results
  • Advances in preclinical research of CAR T-cell therapy for solid tumors will be presented
  • Novel strategies for overcoming hurdles to solid tumor CAR T-cell therapy will be discussed
Panel discussion
09:20

Realizing the promise of ATMPs for patients around the world

  • Working with regulators to navigate scale up challenges in manufacturing
  • Strategies in supply chain and patient delivery
  • Tackling post manufacturing commercialization challenges such as pricing and finding highly skilled experts
  • Durability
10:20

Morning Coffee Break

Mark Sawicki
11:40

Effective Integration Strategies Through a Compliance Unified Ecosystem (CUE)

  • Systems Integration continues to be a major issue in the production and distribution of Advanced Therapies
  • Well-defined strategies for the integration of independent informatics platforms will be critical for future standardization and workflow optimization
  • Cryoport’s Compliance Unified Ecosystem (CUE) is driving standard practices for systems integration in the industry
round tables
12:00

Technology and Strategy Roundtables will run from 12:00-12:45 with 15 minutes for a quick summary from each table at the front of the room. These will take place in the conference rooms: look for you

Technology and Strategy Roundtables will run from 12:00-12:45 with 15 minutes for a quick summary from each table at the front of the room. These will take place in the conference rooms: look for your table number to participate.
1. Raw material supply for the commercial manufacturing of cell and gene therapies
Frank Hecht

Frank Hecht, Vice President Marketing And Sales, CellGenix GmbH

11. Cord blood as a source of new cells
12. Tissue engineering for organ regeneration
Vaidehi Joshi

Vaidehi Joshi, Scientist II, Therapeutics,, Organovo

13. TBC
14. Making allogeneic cell therapy a reality
Devyn Smith

Devyn Smith, Chief Operating Officer and Head Of Strategy, Sigilon

15. Industry-no profit alliances: how to optimize synergies
Elena Beltrami

Elena Beltrami, Business Development Manager, Fondazione Telethon

17. How companies can interact with the regulator and various pitfalls to be aware of
John Johnston

John Johnston, Clinical Assessor, Medicines & Healthcare Products Regulatory Agency

19. Roundtable available
2. Physiological conditions and analytical and monitoring tools for 3D cell cultivations
Cornelia Kasper

Cornelia Kasper, Professor, Biopharmaceutical Production And Technology, B.O.K.U.

21. Neurological applications for ATMPs
22. Development of regenerative medicines for cardiovascular indications
David Mazzo

David Mazzo, Chief Executive Officer, Caladrius Biosciences

23. Renal applications for ATMPs
24. Tackling diabetes with ATMPs
3. TBC (Reserved for Schott)
Sebastian Kress

Sebastian Kress, Post Doc, BOKU

5. Considerations for manufacture scale-up from academia to commercial manufacturing
Johannes Van Der Loo

Johannes Van Der Loo, Clinical Vector Core Director, The Children's Hospital of Philadelphia

9. Exploring the crossover between human and veterinary applications for stem cells
Joanna Miller

Joanna Miller, Chief Scientific Officer, Cell Therapy Sciences

13:00

Lunch

Dr Roy Baynes
IMMUNOTHERAPY
14:20

PD-1 antibodies are transforming cancer therapy both as mono- and in combination

Igor Rudychev
IMMUNOTHERAPY
15:00

From big patient-level data to actionable insights and answering right business questions in oncology

Cynthia Bamdad
IMMUNOTHERAPY
15:20

1st-in-Human CAR T Targets MUC1 Cleavage Product Expressed on Solid Tumors

Giuseppe Mazza
IMMUNOTHERAPY
15:40

Engineered tumor micro-environment using human extracellular matrix for modelling hot and cold tumours.

Hans S Keirstead
IMMUNOTHERAPY
16:00

TBC: Clinical and commercial application of scaled human stem cell derivates in immune-oncology

16:20

Afternoon Break

18:00

Close of Conference for the day - Please join us for an evening drinks reception at the iconic Emirates Stadium

last published: 06/Dec/19 09:35

IMMUNOTHERAPY, Wednesday 1 April 2020

08:55

Opening Remarks

Federico Mingozzi
09:00

Gene therapy 2.0: New clinical data, therapeutic applications and next generation technologies

  • Latest updates on LUXTURNA studies to treat blindness, haemophilia and rare disease
  • Tackling the challenges of viral gene therapies i.e. immunogenicity
  • Developing the next generation of gene therapies, what does the future hold?
Steve Kanner
09:20

Next-generation gene editing technology for allogeneic immune cell therapeutics

  • Next-generation CRISPR-Cas9 technology
  • Significantly enhanced editing specificity
  • Editing in immune cells for generation of functionally tuned therapeutics
Adrian Woolfson
09:40

Repairing the human genome with designed zinc finger editing reagents

  • Overview of Sangamo’s zinc finger protein gene editing technology, including new innovations that facilitate specificity, precision, and gene editing efficiency
  • Will address specific examples of defined therapeutic applications including the generation of reagents suitable for use in tauopathies, Huntington’s disease, and lysosomal storage diseases
Frederic Chereau
10:00

In vivo gene editing paediatric patients with rare diseases

10:20

Networking Refreshments

IMMUNOTHERAPY
11:20

Immuno-oncology for breast cancer

David Pauza
IMMUNOTHERAPY
12:00

At the intersection of genetic medicine and immunotherapy: Clinical experience with a cell and gene therapy for HIV disease

13:00

Neworking Lunch

David Blakey
IMMUNOTHERAPY
14:20

Small activating RNAs as a novel approach for immunotherapy

IMMUNOTHERAPY
14:40

Gene modified Cell Therapy: Gene modified T-Cells for solid tumours

16:20

Networking refreshments

last published: 06/Dec/19 09:35